Anticoagulation reversal in OAC-related intracerebral hemorrhage was independently associated with lower 24-hour (aOR 0.32; 95% CI 0.18-0.56) and 90-day mortality (aOR 0.59; 95% CI 0.35-0.99).
Observational (n=891)
Sí
Does anticoagulation reversal reduce mortality in patients with oral anticoagulant-related intracerebral hemorrhage?
891 patients with oral anticoagulant (OAC)–related intracerebral hemorrhage (ICH) admitted to 18 Spanish stroke centers, mean age 79.0±9.3 years, 60.7% male.
Anticoagulation reversal
No anticoagulation reversal
Reversal administration (primary) and 24-hour and 90-day mortalityhard clinical
Anticoagulation reversal in OAC-related ICH is associated with significantly reduced 24-hour and 90-day mortality, including in severe cases.
Estimación del efecto: aOR 0.32 (95% CI 0.18-0.56)
Abstract Background and aims Oral anticoagulant (OAC)–related intracerebral hemorrhage (ICH) carries high mortality. Despite guideline recommendations, anticoagulation reversal is inconsistently used, particularly in severe presentations. We aimed to identify determinants of reversal administration and its association with mortality in real-world practice. Methods We analyzed data from the prospective, multicenter ARICH registry including consecutive OAC-related ICH patients admitted to 18 Spanish stroke centers (2019–2024). Outcomes included reversal administration (primary) and 24-hour and 90-day mortality. Hierarchical mixed-effects regression models with hospital-level random intercepts were used. Post-hoc analyses evaluated mortality in patients with ICH volume 60 mL and/or GCS ≤5, commonly excluded from RCTs. Results Among 891 patients (mean age 79.0±9.3 years, 541 60.7% male), 678 (76.1%) received reversal. Independent determinants included baseline mRS (aOR 0.84, 95% CI 0.71-0.99), GCS (aOR 1.24, 95% CI 1.13-1.36), ICH volume (per 10-mL increase, aOR 0.86, 95% CI 0.80-0.93), and time since last DOAC dose (per 60-minute increase, aOR 0.94, 95% CI 0.92-0.97). Overall 24-hour mortality was 159/889 (17.9%) and 90-day mortality was 429/887 (48.6%). Reversal was independently associated with lower 24-hour (aOR 0.32, 95% CI 0.18-0.56) and 90-day (aOR 0.59, 95% CI 0.35-0.99) mortality, and with improved outcomes across clinical severity strata: lower 24-hour mortality (Figure 1A) and higher 90-day survival (Figure 1B) (adjusted log-rank P0.05 for all pairwise comparisons). Conclusions In real-world practice, anticoagulation reversal is influenced by perceived prognosis and is independently associated with lower 24-hour and 90-day mortality, including among patients with severe ICH presentations. Conflict of interest David Rodriguez-Luna: nothing to disclose. Olalla Pancorbo: nothing to disclose. Ana Núñez: nothing to disclose. Renato Simonetti: nothing to disclose. Laura Sánchez Cirera: nothing to disclose. Marta Serrano Ponz: nothing to disclose. Rocío Vera Lechuga: nothing to disclose. Cristina Pérez: nothing to disclose. Luis Prats-Sanchez: nothing to disclose. Carlos A. Molina: nothing to disclose. Figure 1 - belongs to Results
Building similarity graph...
Analyzing shared references across papers
Loading...
David Rodriguez-Luna
Hebron University
Olalla Pancorbo
Hebron University
Ana Nuñez Guillen
Bellvitge University Hospital
European Stroke Journal
Vall d'Hebron Hospital Universitari
Hospital de Sant Pau
Hospital Universitario Ramón y Cajal
Building similarity graph...
Analyzing shared references across papers
Loading...
Rodriguez-Luna et al. (Fri,) conducted a observational in Oral anticoagulant-related intracerebral hemorrhage (n=891). Anticoagulation reversal vs. No reversal was evaluated on 24-hour mortality (aOR 0.32, 95% CI 0.18-0.56). Anticoagulation reversal in OAC-related intracerebral hemorrhage was independently associated with lower 24-hour (aOR 0.32; 95% CI 0.18-0.56) and 90-day mortality (aOR 0.59; 95% CI 0.35-0.99).
synapsesocial.com/papers/69fd7fcdbfa21ec5bbf0862f — DOI: https://doi.org/10.1093/esj/aakag023.327